Turn Therapeutics ($TTRX) to Ring the Closing Bell at Nasdaq

Platform

Delivery Platform

Our Plaftorm:
Permafusion

Permafusion® is a revolutionary way of permanently and stably fusing liquid into oil without an emulsifier. This allows us to carry pharmaceutical ingredients through the skin, nails, and mucous membranes more effectively, reaching deeper layers via lipid bilayers for targeted healing while minimizing side effects and maximizing bioavailability.

Minimizes

Toxicity

Minimizes

Irritation

Minimizes

Sensitization

How it Works

PermaFusion® is a first-of-its-kind technology that fuses liquid and oil to create formulas capable of penetrating deep into skin, nail, and mucous membranes.

Step 1

Preparation of Active Solution

We begin with a liquid that holds the active pharmaceutical ingredient.

Step 2

Introduction into the Oil Phase

This liquid is added into an oil carrier using a patented multi-step mixing process. Unlike typical blends that require chemical emulsifiers to mix oil and water, PermaFusion® uses a proprietary high-energy process.

Step 3

High-Energy Fusion

The oil and water mixture undergoes a vigorous mixing process. This physically fuses the two phases together at a nanoscopic level, creating a stable formula that doesn’t need added chemicals to hold it together.

Step 4

Nano-Suspension is Formed

Within each droplet of oil, tiny pockets of liquids are suspended. Each liquid droplet contains the active ingredient, keeping it permanently stable inside the oil.

Step 5

Heal More, Harm Less

Because the concentration of ingredients is low and targeted, side effects are minimized while effectiveness is maximized. This is how PermaFusion® brings smarter, safer healing to people.

PermaFusion Revolutionizes drug delivery

It solves one of the biggest problems in drug delivery: how to safely deliver pharmaceutical ingredients through skin, nails, and mucous membranes without relying on needles or pills. PermaFusion® allows for targeted delivery at low concentrations, reducing risk while improving results.

With over 200,000 human uses across multiple indications and zero reported adverse events, it has already proven safe and effective as a medical device, and is in clinical trials for use as a drug treatment targeting multiple indications.

We’ve used the same platform to successfully suspend and maintain viability of a live vaccine in an oil carrier at room temperature — a breakthrough that could transform how vaccines are stored and administered worldwide.

Everything we build stems from this foundational platform, making it easier to scale and more cost-effective to expand across multiple indications.

The possibilities for PermaFusion are as endless as the imagination.

Explore
Our Portfolio

Explore
Our Pipeline
  • Westlake Village, CA
  • 1-818-564-4011

Sign Up for Updates

Enter your information to receive the latest product updates and news from Turn Therapeutics.

Muhammad Zubair

Controller

Zubair, Controller, has 5+ years of accounting and finance management experience in companies ranging from medium-sized companies to pulicly traded multinationals. Zubair is a member of the Institute of Chartered Accountants of Pakistan and holds a Master’s degree in accounting & finance (Equivalent). 

Linkedin

Zuraiz Chaudhary, CPA

Chief Accounting Officer, VP Finance

Zuraiz, VP of Finance and Chief Accounting Officer, is a seasoned finance & accounting executive with more than a decade experience in working with PwC, EY and KPMG.  Zuraiz is a licensed CPA in California and Texas, has a bachelor’s in business administration from Asia-e University (Malaysia), is a member of the Institute of Chartered Accountants of Pakistan. Zuraiz specializes in financial reporting, SOX compliance and internal controls.

Linkedin

Dr. Neil Ghodadra, MD

Chief Medical Officer, Board Director

Dr. Neil Ghodadra, Board Certified Orthopedic Surgeon, joined Turn in Q3 2017. Renowned for surgical skill and orthopedic research, he graduated Magna Cum Laude from Duke University with a BS in Biology, and with Honors from Duke Medical School. His residency at Rush Medical Center focused on sports medicine, specializing in knee & shoulder surgery.

Linkedin

Bradley Burnam

Chief Executive Officer & Founder

Bradley Burnam, Founder & CEO, developed PermaFusion®, a patented drug delivery system, to combat his hospital-acquired skin infection. This innovation led to Hexagen™ Wound Dressing, Turn’s flagship product. Burnam, a self-taught regulatory and formulation expert, secured Turn’s first three FDA clearances solo before assembling a skilled team.

Linkedin

Subscribe to the Founder's Blog

Enter your information to subscribe for the latest updates from our Founder’s Blog.